These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Drug safety: the viewpoint of the pharmaceutical manufacturing industry. Wigle WW Can Med Assoc J; 1968 Feb; 98(6):314-7. PubMed ID: 5636099 [No Abstract] [Full Text] [Related]
3. [Drug dosage form and action]. Zathurecký L Med Klin; 1974 Apr; 69(16):667-70. PubMed ID: 4837397 [No Abstract] [Full Text] [Related]
4. Bioavailability of drugs. J Ir Med Assoc; 1973 Oct; 66(19):547 passim. PubMed ID: 4759091 [No Abstract] [Full Text] [Related]
5. Dosage form design of investigational drugs in cancer chemotherapy. Davignon JP Bull Parenter Drug Assoc; 1969; 23(2):83-9. PubMed ID: 4975731 [No Abstract] [Full Text] [Related]
6. Parenteral development of clindamycin-2-phosphate. Riebe KW; Oesterling TO Bull Parenter Drug Assoc; 1972; 26(3):139-46. PubMed ID: 5035118 [No Abstract] [Full Text] [Related]
7. Brain to bottle time. Burt RA Proc R Soc Med; 1974 Jun; 67(7):584-6. PubMed ID: 4211842 [No Abstract] [Full Text] [Related]
8. Lack of pediatric drug formulations. Nahata MC Pediatrics; 1999 Sep; 104(3 Pt 2):607-9. PubMed ID: 10469800 [TBL] [Abstract][Full Text] [Related]
9. Bioavailability of indomethacin in man. Baer JE; Hucker HB; Duggan DE Ann Clin Res; 1974; 6(0):suppl 11:44-7. PubMed ID: 4211834 [No Abstract] [Full Text] [Related]
10. Current good manufacturing practice regulations. Bumiller J Bull Parenter Drug Assoc; 1971; 25(5):222-5. PubMed ID: 5094094 [No Abstract] [Full Text] [Related]
12. [Progress in drug technology in the years 1968 and 1969]. Chalabala M; Malý J; Burelová A Cesk Farm; 1970 Nov; 19(9):332-60. PubMed ID: 4926371 [No Abstract] [Full Text] [Related]
13. Drug bioequivalence. Recommendations from the Drug Bioequivalence Study Panel to the Office of Technology Assessment, Congress of the United States. J Pharmacokinet Biopharm; 1974 Oct; 2(5):433-66. PubMed ID: 4452945 [No Abstract] [Full Text] [Related]
15. The other path for follow-ons. Nat Biotechnol; 2008 Jul; 26(7):715. PubMed ID: 18612272 [TBL] [Abstract][Full Text] [Related]
16. Generic-therapeutic equivalence--enigma or myth? Shirkey HC Hawaii Med J; 1970; 29(3):201-2. PubMed ID: 5416016 [No Abstract] [Full Text] [Related]
17. ASHP technical assistance bulletin on compounding nonsterile products in pharmacies. American Society of Hospital Pharmacists. Am J Hosp Pharm; 1994 Jun; 51(11):1441-8. PubMed ID: 7942879 [No Abstract] [Full Text] [Related]
18. Implementing United States Pharmacopeia Chapter <1163>: Quality assurance in pharmaceutical compounding, part 4: cleaning and packaging. Allen LV Int J Pharm Compd; 2012; 16(5):405-14. PubMed ID: 23072201 [TBL] [Abstract][Full Text] [Related]
19. Establishment of an equivalence acceptance criterion for accelerated stability studies. Burdick RK; Sidor L J Biopharm Stat; 2013; 23(4):730-43. PubMed ID: 23799811 [TBL] [Abstract][Full Text] [Related]
20. [Pharmacology and practical therapy. Principles for the selection of application form of a drug and its mode of origin]. Levy G; Barr WH Internist (Berl); 1973 Dec; 14(12):661-7. PubMed ID: 4593013 [No Abstract] [Full Text] [Related] [Next] [New Search]